Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AKRO | US
-0.97
-3.32%
Healthcare
Biotechnology
30/06/2024
04/10/2024
28.24
27.93
29.04
27.90
Akero Therapeutics Inc. a clinical-stage company engages in the development of transformational treatments for patients with serious metabolic diseases including non-alcoholic steatohepatitis (NASH) a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX) an analog of fibroblast growth factor 21 which protects against cellular stress and regulates metabolism of lipids carbohydrates and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals Inc. and changed its name to Akero Therapeutics Inc. in May 2018. Akero Therapeutics Inc. was incorporated in 2017 and is headquartered in South San Francisco California.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
Price Below SMA10D
Midcap (2B - 10B USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
39.2%1 month
37.9%3 months
47.0%6 months
53.8%-
-
2.46
0.05
0.04
-6.77
-
-
-234.17M
2.04B
2.04B
-
-
-
-
-28.87
16.06
10.62
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.62
Range1M
4.86
Range3M
8.85
Rel. volume
1.05
Price X volume
15.37M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Novavax Inc | NVAX | Biotechnology | 13.61 | 2.18B | -7.29% | n/a | -54.03% |
Vericel Corporation | VCEL | Biotechnology | 43.36 | 2.17B | 6.54% | 4.32K | 39.42% |
Centessa Pharmaceuticals plc American Depositary Shares | CNTA | Biotechnology | 15.94 | 2.05B | -1.97% | n/a | 29.85% |
Celldex Therapeutics Inc | CLDX | Biotechnology | 30.65 | 2.03B | 1.46% | n/a | 0.29% |
Harmony Biosciences Holdings Inc. | HRMY | Biotechnology | 34.6 | 2.00B | -2.73% | 20.07 | 40.71% |
Maravai LifeSciences Holdings Inc | MRVI | Biotechnology | 7.89 | 1.99B | -0.13% | n/a | 128.60% |
Ligand Pharmaceuticals Incorporated | LGND | Biotechnology | 104.78 | 1.95B | 4.83% | 42.52 | 0.98% |
BEAM THERAPEUTICS INC. | BEAM | Biotechnology | 23.41 | 1.93B | -0.38% | n/a | 19.35% |
Galapagos NV | GLPG | Biotechnology | 29.19 | 1.92B | 2.89% | 55.25 | 0.00% |
Mirum Pharmaceuticals Inc | MIRM | Biotechnology | 39.26 | 1.87B | -5.37% | n/a | 138.24% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -6.77 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 2.46 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 47.01 | 74.67 | Lower Risk |
Debt to Equity | 0.05 | -1.82 | Expensive |
Debt to Assets | 0.04 | 0.26 | Cheaper |
Market Cap | 2.04B | 3.73B | Emerging |